Lipids	B:C0023779
and	O
lipid	O
changes	O
with	O
synthetic	O
and	O
biologic	O
disease	I:C1303166
-	I:C1303166
modifying	I:C1303166
antirheumatic	I:C1303166
drug	I:C1303166
therapy	I:C1303166
in	O
rheumatoid	O
arthritis	I:C0003873
:	O
implications	O
for	O
cardiovascular	O
risk	O
.	O

Lipids	O
and	O
lipid	B:C0023779
changes	O
with	O
synthetic	O
and	O
biologic	O
disease	I:C1303166
-	I:C1303166
modifying	I:C1303166
antirheumatic	I:C1303166
drug	I:C1303166
therapy	I:C1303166
in	O
rheumatoid	O
arthritis	I:C0003873
:	O
implications	O
for	O
cardiovascular	O
risk	O
.	O

Lipids	O
and	O
lipid	O
changes	O
with	O
synthetic	B:C4054347
and	O
biologic	O
disease	I:C1303166
-	I:C1303166
modifying	I:C1303166
antirheumatic	I:C1303166
drug	I:C1303166
therapy	I:C1303166
in	O
rheumatoid	O
arthritis	I:C0003873
:	O
implications	O
for	O
cardiovascular	O
risk	O
.	O

Lipids	O
and	O
lipid	O
changes	O
with	O
synthetic	O
and	O
biologic	B:C1303166
disease	I:C1303166
-	I:C1303166
modifying	I:C1303166
antirheumatic	I:C1303166
drug	I:C1303166
therapy	I:C1303166
in	O
rheumatoid	O
arthritis	I:C0003873
:	O
implications	O
for	O
cardiovascular	O
risk	O
.	O

Lipids	O
and	O
lipid	O
changes	O
with	O
synthetic	O
and	O
biologic	O
disease	I:C1303166
-	I:C1303166
modifying	I:C1303166
antirheumatic	I:C1303166
drug	I:C1303166
therapy	I:C1303166
in	O
rheumatoid	B:C0003873
arthritis	I:C0003873
:	O
implications	O
for	O
cardiovascular	O
risk	O
.	O

To	O
highlight	O
recently	O
published	O
studies	B:C2603343
addressing	O
lipid	O
changes	O
with	O
disease	O
-	I:C0242708
modifying	I:C0242708
antirheumatic	I:C0242708
drug	I:C0242708
use	O
and	O
outline	O
implications	O
on	O
cardiovascular	O
outcomes	O
in	O
rheumatoid	O
arthritis	I:C0003873
(	O
rheumatoid	O
arthritis	I:C0003873
)	O
.	O

To	O
highlight	O
recently	O
published	O
studies	O
addressing	O
lipid	B:C0023779
changes	O
with	O
disease	O
-	I:C0242708
modifying	I:C0242708
antirheumatic	I:C0242708
drug	I:C0242708
use	O
and	O
outline	O
implications	O
on	O
cardiovascular	O
outcomes	O
in	O
rheumatoid	O
arthritis	I:C0003873
(	O
rheumatoid	O
arthritis	I:C0003873
)	O
.	O

To	O
highlight	O
recently	O
published	O
studies	O
addressing	O
lipid	O
changes	O
with	O
disease	B:C0242708
-	I:C0242708
modifying	I:C0242708
antirheumatic	I:C0242708
drug	I:C0242708
use	O
and	O
outline	O
implications	O
on	O
cardiovascular	O
outcomes	O
in	O
rheumatoid	O
arthritis	I:C0003873
(	O
rheumatoid	O
arthritis	I:C0003873
)	O
.	O

To	O
highlight	O
recently	O
published	O
studies	O
addressing	O
lipid	O
changes	O
with	O
disease	O
-	I:C0242708
modifying	I:C0242708
antirheumatic	I:C0242708
drug	I:C0242708
use	O
and	O
outline	O
implications	O
on	O
cardiovascular	B:C3887460
outcomes	O
in	O
rheumatoid	O
arthritis	I:C0003873
(	O
rheumatoid	O
arthritis	I:C0003873
)	O
.	O

To	O
highlight	O
recently	O
published	O
studies	O
addressing	O
lipid	O
changes	O
with	O
disease	O
-	I:C0242708
modifying	I:C0242708
antirheumatic	I:C0242708
drug	I:C0242708
use	O
and	O
outline	O
implications	O
on	O
cardiovascular	O
outcomes	O
in	O
rheumatoid	B:C0003873
arthritis	I:C0003873
(	O
rheumatoid	O
arthritis	I:C0003873
)	O
.	O

To	O
highlight	O
recently	O
published	O
studies	O
addressing	O
lipid	O
changes	O
with	O
disease	O
-	I:C0242708
modifying	I:C0242708
antirheumatic	I:C0242708
drug	I:C0242708
use	O
and	O
outline	O
implications	O
on	O
cardiovascular	O
outcomes	O
in	O
rheumatoid	O
arthritis	I:C0003873
(	O
rheumatoid	B:C0003873
arthritis	I:C0003873
)	O
.	O

Growing	O
evidence	O
suggests	O
lower	O
lipid	B:C0428460
levels	I:C0428460
are	O
present	O
in	O
patients	O
with	O
active	O
rheumatoid	O
arthritis	I:C0003873
vs.	O
general	O
population	I:C0683971
,	O
and	O
significant	O
modifications	O
of	O
lipid	O
profile	O
with	O
inflammation	O
suppression	O
.	O

Growing	O
evidence	O
suggests	O
lower	O
lipid	O
levels	I:C0428460
are	O
present	B:C0150312
in	O
patients	O
with	O
active	O
rheumatoid	O
arthritis	I:C0003873
vs.	O
general	O
population	I:C0683971
,	O
and	O
significant	O
modifications	O
of	O
lipid	O
profile	O
with	O
inflammation	O
suppression	O
.	O

Growing	O
evidence	O
suggests	O
lower	O
lipid	O
levels	I:C0428460
are	O
present	O
in	O
patients	O
with	O
active	O
rheumatoid	B:C0003873
arthritis	I:C0003873
vs.	O
general	O
population	I:C0683971
,	O
and	O
significant	O
modifications	O
of	O
lipid	O
profile	O
with	O
inflammation	O
suppression	O
.	O

Growing	O
evidence	O
suggests	O
lower	O
lipid	O
levels	I:C0428460
are	O
present	O
in	O
patients	O
with	O
active	O
rheumatoid	O
arthritis	I:C0003873
vs.	O
general	B:C0683971
population	I:C0683971
,	O
and	O
significant	O
modifications	O
of	O
lipid	O
profile	O
with	O
inflammation	O
suppression	O
.	O

Growing	O
evidence	O
suggests	O
lower	O
lipid	O
levels	I:C0428460
are	O
present	O
in	O
patients	O
with	O
active	O
rheumatoid	O
arthritis	I:C0003873
vs.	O
general	O
population	I:C0683971
,	O
and	O
significant	O
modifications	B:C3840684
of	O
lipid	O
profile	O
with	O
inflammation	O
suppression	O
.	O

Growing	O
evidence	O
suggests	O
lower	O
lipid	O
levels	I:C0428460
are	O
present	O
in	O
patients	O
with	O
active	O
rheumatoid	O
arthritis	I:C0003873
vs.	O
general	O
population	I:C0683971
,	O
and	O
significant	O
modifications	O
of	O
lipid	B:C0023779
profile	O
with	O
inflammation	O
suppression	O
.	O

Growing	O
evidence	O
suggests	O
lower	O
lipid	O
levels	I:C0428460
are	O
present	O
in	O
patients	O
with	O
active	O
rheumatoid	O
arthritis	I:C0003873
vs.	O
general	O
population	I:C0683971
,	O
and	O
significant	O
modifications	O
of	O
lipid	O
profile	O
with	O
inflammation	B:C0021368
suppression	O
.	O

Growing	O
evidence	O
suggests	O
lower	O
lipid	O
levels	I:C0428460
are	O
present	O
in	O
patients	O
with	O
active	O
rheumatoid	O
arthritis	I:C0003873
vs.	O
general	O
population	I:C0683971
,	O
and	O
significant	O
modifications	O
of	O
lipid	O
profile	O
with	O
inflammation	O
suppression	B:C0301625
.	O

Increase	O
in	O
lipid	B:C0428460
levels	I:C0428460
in	O
patients	O
with	O
rheumatoid	O
arthritis	I:C0003873
on	O
synthetic	O
and	O
biological	O
disease	O
-	I:C0242708
modifying	I:C0242708
antirheumatic	I:C0242708
drugs	I:C0242708
may	O
be	O
accompanied	O
by	O
antiatherogenic	O
changes	O
in	O
lipid	O
composition	O
and	O
function	O
.	O

Increase	O
in	O
lipid	O
levels	I:C0428460
in	O
patients	O
with	O
rheumatoid	B:C0003873
arthritis	I:C0003873
on	O
synthetic	O
and	O
biological	O
disease	O
-	I:C0242708
modifying	I:C0242708
antirheumatic	I:C0242708
drugs	I:C0242708
may	O
be	O
accompanied	O
by	O
antiatherogenic	O
changes	O
in	O
lipid	O
composition	O
and	O
function	O
.	O

Increase	O
in	O
lipid	O
levels	I:C0428460
in	O
patients	O
with	O
rheumatoid	O
arthritis	I:C0003873
on	O
synthetic	B:C4054347
and	O
biological	O
disease	O
-	I:C0242708
modifying	I:C0242708
antirheumatic	I:C0242708
drugs	I:C0242708
may	O
be	O
accompanied	O
by	O
antiatherogenic	O
changes	O
in	O
lipid	O
composition	O
and	O
function	O
.	O

Increase	O
in	O
lipid	O
levels	I:C0428460
in	O
patients	O
with	O
rheumatoid	O
arthritis	I:C0003873
on	O
synthetic	O
and	O
biological	O
disease	B:C0242708
-	I:C0242708
modifying	I:C0242708
antirheumatic	I:C0242708
drugs	I:C0242708
may	O
be	O
accompanied	O
by	O
antiatherogenic	O
changes	O
in	O
lipid	O
composition	O
and	O
function	O
.	O

Increase	O
in	O
lipid	O
levels	I:C0428460
in	O
patients	O
with	O
rheumatoid	O
arthritis	I:C0003873
on	O
synthetic	O
and	O
biological	O
disease	O
-	I:C0242708
modifying	I:C0242708
antirheumatic	I:C0242708
drugs	I:C0242708
may	O
be	O
accompanied	O
by	O
antiatherogenic	O
changes	O
in	O
lipid	B:C0023779
composition	O
and	O
function	O
.	O

Increase	O
in	O
lipid	O
levels	I:C0428460
in	O
patients	O
with	O
rheumatoid	O
arthritis	I:C0003873
on	O
synthetic	O
and	O
biological	O
disease	O
-	I:C0242708
modifying	I:C0242708
antirheumatic	I:C0242708
drugs	I:C0242708
may	O
be	O
accompanied	O
by	O
antiatherogenic	O
changes	O
in	O
lipid	O
composition	B:C0486616
and	O
function	O
.	O

The	O
impact	O
of	O
lipid	B:C0023779
changes	O
on	O
cardiovascular	O
outcomes	O
in	O
rheumatoid	O
arthritis	I:C0003873
is	O
a	O
subject	O
of	O
active	O
research	I:C0035168
.	O

The	O
impact	O
of	O
lipid	O
changes	O
on	O
cardiovascular	B:C3887460
outcomes	O
in	O
rheumatoid	O
arthritis	I:C0003873
is	O
a	O
subject	O
of	O
active	O
research	I:C0035168
.	O

The	O
impact	O
of	O
lipid	O
changes	O
on	O
cardiovascular	O
outcomes	O
in	O
rheumatoid	B:C0003873
arthritis	I:C0003873
is	O
a	O
subject	O
of	O
active	O
research	I:C0035168
.	O

The	O
impact	O
of	O
lipid	O
changes	O
on	O
cardiovascular	O
outcomes	O
in	O
rheumatoid	O
arthritis	I:C0003873
is	O
a	O
subject	O
of	O
active	B:C0035168
research	I:C0035168
.	O

The	O
role	O
of	O
lipids	B:C0023779
in	O
cardiovascular	O
risk	O
in	O
rheumatoid	O
arthritis	I:C0003873
may	O
be	O
overpowered	O
by	O
the	O
benefits	O
of	O
inflammation	O
suppression	O
with	O
antirheumatic	O
medication	I:C0003191
use	O
.	O

The	O
role	O
of	O
lipids	O
in	O
cardiovascular	O
risk	O
in	O
rheumatoid	B:C0003873
arthritis	I:C0003873
may	O
be	O
overpowered	O
by	O
the	O
benefits	O
of	O
inflammation	O
suppression	O
with	O
antirheumatic	O
medication	I:C0003191
use	O
.	O

The	O
role	O
of	O
lipids	O
in	O
cardiovascular	O
risk	O
in	O
rheumatoid	O
arthritis	I:C0003873
may	O
be	O
overpowered	O
by	O
the	O
benefits	O
of	O
inflammation	B:C0021368
suppression	O
with	O
antirheumatic	O
medication	I:C0003191
use	O
.	O

The	O
role	O
of	O
lipids	O
in	O
cardiovascular	O
risk	O
in	O
rheumatoid	O
arthritis	I:C0003873
may	O
be	O
overpowered	O
by	O
the	O
benefits	O
of	O
inflammation	O
suppression	B:C0301625
with	O
antirheumatic	O
medication	I:C0003191
use	O
.	O

The	O
role	O
of	O
lipids	O
in	O
cardiovascular	O
risk	O
in	O
rheumatoid	O
arthritis	I:C0003873
may	O
be	O
overpowered	O
by	O
the	O
benefits	O
of	O
inflammation	O
suppression	O
with	O
antirheumatic	B:C0003191
medication	I:C0003191
use	O
.	O

Recommendations	B:C1272213
on	I:C1272213
lipid	I:C1272213
management	I:C1272213
in	O
rheumatoid	O
arthritis	I:C0003873
are	O
evolving	O
but	O
uncertainty	O
exists	O
regarding	O
frequency	O
of	O
lipid	O
testing	O
and	O
goals	O
of	O
treatment	O
.	O

Recommendations	O
on	I:C1272213
lipid	I:C1272213
management	I:C1272213
in	O
rheumatoid	B:C0003873
arthritis	I:C0003873
are	O
evolving	O
but	O
uncertainty	O
exists	O
regarding	O
frequency	O
of	O
lipid	O
testing	O
and	O
goals	O
of	O
treatment	O
.	O

Recommendations	O
on	I:C1272213
lipid	I:C1272213
management	I:C1272213
in	O
rheumatoid	O
arthritis	I:C0003873
are	O
evolving	O
but	O
uncertainty	O
exists	O
regarding	O
frequency	O
of	O
lipid	B:C0023779
testing	O
and	O
goals	O
of	O
treatment	O
.	O

Recommendations	O
on	I:C1272213
lipid	I:C1272213
management	I:C1272213
in	O
rheumatoid	O
arthritis	I:C0003873
are	O
evolving	O
but	O
uncertainty	O
exists	O
regarding	O
frequency	O
of	O
lipid	O
testing	O
and	O
goals	B:C0679840
of	O
treatment	O
.	O

Knowledge	B:C0376554
about	O
quantitative	O
and	O
qualitative	O
lipid	O
changes	O
in	O
rheumatoid	O
arthritis	I:C0003873
is	O
expanding	O
.	O

Knowledge	O
about	O
quantitative	O
and	O
qualitative	O
lipid	B:C0023779
changes	O
in	O
rheumatoid	O
arthritis	I:C0003873
is	O
expanding	O
.	O

Knowledge	O
about	O
quantitative	O
and	O
qualitative	O
lipid	O
changes	O
in	O
rheumatoid	B:C0003873
arthritis	I:C0003873
is	O
expanding	O
.	O

Knowledge	O
about	O
quantitative	O
and	O
qualitative	O
lipid	O
changes	O
in	O
rheumatoid	O
arthritis	I:C0003873
is	O
expanding	B:C0205229
.	O

The	O
relative	O
role	O
of	O
lipids	B:C0023779
in	O
cardiovascular	O
risk	O
in	O
the	O
context	O
of	O
systemic	O
inflammation	O
and	O
antirheumatic	O
therapy	I:C1303166
remains	O
uncertain	O
,	O
delaying	O
development	O
of	O
effective	O
strategies	O
for	O
cardiovascular	O
risk	O
management	O
in	O
rheumatoid	O
arthritis	I:C0003873
.	O

The	O
relative	O
role	O
of	O
lipids	O
in	O
cardiovascular	O
risk	O
in	O
the	O
context	O
of	O
systemic	O
inflammation	O
and	O
antirheumatic	B:C1303166
therapy	I:C1303166
remains	O
uncertain	O
,	O
delaying	O
development	O
of	O
effective	O
strategies	O
for	O
cardiovascular	O
risk	O
management	O
in	O
rheumatoid	O
arthritis	I:C0003873
.	O

The	O
relative	O
role	O
of	O
lipids	O
in	O
cardiovascular	O
risk	O
in	O
the	O
context	O
of	O
systemic	O
inflammation	O
and	O
antirheumatic	O
therapy	I:C1303166
remains	O
uncertain	O
,	O
delaying	O
development	O
of	O
effective	O
strategies	O
for	O
cardiovascular	O
risk	O
management	B:C0376636
in	O
rheumatoid	O
arthritis	I:C0003873
.	O

The	O
relative	O
role	O
of	O
lipids	O
in	O
cardiovascular	O
risk	O
in	O
the	O
context	O
of	O
systemic	O
inflammation	O
and	O
antirheumatic	O
therapy	I:C1303166
remains	O
uncertain	O
,	O
delaying	O
development	O
of	O
effective	O
strategies	O
for	O
cardiovascular	O
risk	O
management	O
in	O
rheumatoid	B:C0003873
arthritis	I:C0003873
.	O

Studies	B:C2603343
are	O
underway	O
to	O
address	O
these	O
knowledge	O
gaps	O
and	O
may	O
be	O
expected	O
to	O
inform	O
cardiovascular	O
risk	O
management	O
in	O
rheumatoid	O
arthritis	I:C0003873
and	O
the	O
general	O
population	I:C0683971
.	O

Studies	O
are	O
underway	O
to	O
address	O
these	O
knowledge	B:C0376554
gaps	O
and	O
may	O
be	O
expected	O
to	O
inform	O
cardiovascular	O
risk	O
management	O
in	O
rheumatoid	O
arthritis	I:C0003873
and	O
the	O
general	O
population	I:C0683971
.	O

Studies	O
are	O
underway	O
to	O
address	O
these	O
knowledge	O
gaps	O
and	O
may	O
be	O
expected	O
to	O
inform	O
cardiovascular	O
risk	O
management	B:C0376636
in	O
rheumatoid	O
arthritis	I:C0003873
and	O
the	O
general	O
population	I:C0683971
.	O

Studies	O
are	O
underway	O
to	O
address	O
these	O
knowledge	O
gaps	O
and	O
may	O
be	O
expected	O
to	O
inform	O
cardiovascular	O
risk	O
management	O
in	O
rheumatoid	B:C0003873
arthritis	I:C0003873
and	O
the	O
general	O
population	I:C0683971
.	O

Studies	O
are	O
underway	O
to	O
address	O
these	O
knowledge	O
gaps	O
and	O
may	O
be	O
expected	O
to	O
inform	O
cardiovascular	O
risk	O
management	O
in	O
rheumatoid	O
arthritis	I:C0003873
and	O
the	O
general	B:C0683971
population	I:C0683971
.	O

